BW-40202
/ Argo Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 15, 2025
Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
(PRNewswire)
- "The study is expected to commence in January 2026."
New P2 trial • Paroxysmal Nocturnal Hemoglobinuria
1 to 1
Of
1
Go to page
1